Ligand Pharmaceuticals, Inc. (LGND) Tops Q2 EPS by 5c; Issues Light Q4 Proft Outlook

October 30, 2013 8:37 AM

Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q2 EPS of $0.12, $0.05 better than the analyst estimate of $0.07. Revenue for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found